drugset / Trial / NCT00109577

Clinical Trial of a Nutritional Supplement in Adults With Bipolar Disorder

NCT00109577 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the trial was to determine whether a 36-ingredient micronutrient supplement (primarily vitamins and minerals) is beneficial for the treatment of bipolar disorder, when studied under randomized and fully blinded conditions and compared to a placebo. The supplement is referred to as MCN36, because it contains 36 nutrients. Based on the preliminary research on this supplement, it is hypothesized that patients who take MCN36 for 8 weeks will experience improved mood stability relative to those who take the placebo. All participants must live EITHER in the vicinity of Calgary, Alberta, Canada, OR in the area of San Diego, California.

Timeline

Start
2005-04
Primary completion
2009-03
Completion
2009-03

Outcome

Outcome not reported

Stopped (Enrollment): “Unable to recruit large enough sample; large expectancy effects but no adverse events”

Drugs

EvaluationDrugModalityDoseRoute
Subject MCN36 Unknown — —

Indications